Table 2.

Some important vaccines developed for medical management of pandemics[48–50]

Year	Industry	Vaccine type	Brand name	Salient feature(s)
2004	Sanofi Pasteur	Inactivated vaccine	-	It is an inactivated vaccine made from an H5N1 virus isolated in southeast Asia in 2004. Vaccine is produced from virus grown in fertile hen eggs and inactivated by either formaldehyde or beta – propiolctone. It is given by intramuscular injection.
2006	MedImmune	Live attenuated influenza vaccine (LAIV)	MedImmue FluMist R influenza vaccine	This vaccine is based on combination of modified protein derived from virulent H5N1 flu virus with protein from an attenuated flu strain. LAIV has been license by FDA in 2003. It contain live but attenuated (weakened) influenza virus. It is sprayed into nostril instead of injected into muscle.
2008	-	Cell culture vaccine	-	Vaccine is created by using cell of monkeys instead of chicken's egg which reduces the time of development of vaccine.
2009	-	Recombinant vaccine	-	Use of Human Monoclonal antibodies that neutralize different strain of influenza A virus. Subunit influenza vaccines have been prepared from recombinant haemagglutin and neuraminidase protein expressed in insect cells by baculoviruses.
2009	NOVAVAX	DNA vaccinevirus like particle (VLP) vaccine candidate	-	Provide broad protection against strains of Avian Infiuenza, mainly 3 strains are used A/Qinghai(clade2.2),aaA. It present promising approach to vaccination, evoking full range of immune response. DNA vaccines with constructs encoding the nucleoprotein(NP), haemagglutin, neuraminidase, matrix protein 1(M1) and non structural protein 1 of influenza virus.
2009	Delsite Biotechnologies	Live attenuated vaccine	Gelvac TM Nasal powder	It is preservative and adjuvant free and allows needle free administration and it reduce the cost of stockpiling of strategic vaccine.